Escalating conflict in the Middle East has forced pharmaceutical companies to reroute temperature-sensitive cancer drugs, risking shortages within weeks as key air cargo hubs remain closed.
Conflict Cripples Key Air Hubs
The ongoing Middle East conflict, ignited by U.S. and Israeli attacks on Iran two weeks ago and escalated by Iranian retaliatory strikes, has crippled key air transit hubs across the region Reuters. Major airports in Dubai, Abu Dhabi, and Doha—critical nodes connecting Europe, Asia, and Africa—have been forced to close, severing primary cargo routes for time-sensitive goods.
This disruption hits pharmaceutical supply chains with particular severity. The Gulf region depends heavily on imports, and many life-saving treatments, especially cancer drugs like monoclonal antibodies, require strict cold-chain storage and have short shelf lives Reuters. Overland shipping, while being explored, is less practical for such sensitive cargo due to extended transit times.
Alternative Routes and Their Limitations
Pharmaceutical companies are scrambling to identify alternative routes. Executives report diverting flights to airports in Jeddah and Riyadh, Saudi Arabia, and utilizing hubs in Istanbul and Oman Reuters. Some Europe-Asia cargo previously routed through Dubai or Doha is now being redirected via China or Singapore, though sea routes remain impractical due to longer journeys and the closure of the Strait of Hormuz.
Industry data underscores the scale of the problem. Wouter Dewulf, a professor at the Antwerp Management School, notes that over a fifth of global air cargo—the main conduit for critical drugs and vaccines—is exposed to Middle East disruption Reuters. However, establishing new “cold-chain corridors” is not instantaneous and may not always be feasible.
Industry Response and Rising Risks
Logistics providers assert the industry is coping for now. Dorothee Becher of Kuehne+Nagel states that carriers are utilizing Jeddah, Riyadh, and Oman, with land routes reaching final markets Reuters. “I do not see any risk yet that the inventory would go dramatically down,” she remarks, noting healthcare cargo prioritization.
Yet, maintaining flow is a daily challenge. Doaa Fathallah of Marken describes round-the-clock rerouting as airspace restrictions shift rapidly Reuters. Longer transit times and higher fuel costs are driving up transportation fees, alongside increased use of dry ice to preserve drug temperatures.
The risks extend beyond the medicines themselves. Shortages of ancillary items like vial stoppers, IV bag plastics, and packaging materials could indirectly constrain drug availability Reuters. “In some cases, it’s the little stopper on the vial where the dosage is extracted,” notes David Weeks of Moody’s.
What This Means for Patients
The stakes are highest for oncology medicines. Prashant Yadav, senior fellow for global health at the Council on Foreign Relations, explains that stocks of short shelf-life, temperature-sensitive drugs typically last about three months Reuters. Cancer treatments, particularly monoclonal antibodies, are among the most vulnerable. Delays can force patients to restart therapy or face disease progression.
Some customers have already warned they could deplete supplies within four to six weeks if the crisis persists Reuters. Over 100 pharma and logistics experts convened in a recent webinar hosted by Pharma.Aero to address the Gulf crisis and its supply-chain implications.
As the conflict continues, the pressure on global pharmaceutical supply chains will intensify. The Gulf’s dependence on air imports for critical, time-sensitive therapies exposes a fragile vulnerability—one that may test the resilience of healthcare systems in the region and beyond.
For ongoing, authoritative analysis of how global conflicts impact critical supply chains, trust onlytrustedinfo.com to deliver the fastest, most insightful coverage. Our team of experts cuts through the noise to explain why these disruptions matter and what they mean for you.
